内分泌治療薬の世界市場レポート 2025年

内分泌治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8.60％で503億7,000万米ドルに成長します。予測期間中に予想される成長は、糖尿病人口の増加、内分泌疾患の有病率の増加、ホルモンバランスの乱れに直面する青少年の増加、肥満率の増加などの要因に起因すると考えられます。予測期間の主な動向としては、技術の進歩、先進ドラッグデリバリーシステムの採用、デジタルヘルスソリューションの統合、精密医療、併用療法などが挙げられます。

内分泌疾患の有病率の上昇が内分泌治療薬市場の成長を促進しています。内分泌疾患は内分泌系に影響を及ぼす疾患で、ホルモンの産生や調節の不均衡につながり、正常な身体機能を乱します。内分泌疾患の有病率増加の要因としては、ライフスタイルの変化、高齢化、診断方法の改善などが挙げられ、これらはすべてこれらの疾患の認知度や発生率の上昇につながっています。内分泌治療薬は、ホルモンレベルを調整し、腺機能障害に対処し、ホルモンバランスを回復させることにより、これらの疾患を管理し、健康上の転帰を改善するように設計されています。例えば、2023年5月、米国国立医学図書館は、米国では約1,300万人（人口の約4.78％）が未診断の内分泌疾患に苦しんでおり、中でも甲状腺疾患が最も多く、内分泌診療所で治療を受けている患者の30～40％が罹患していると報告しました。この内分泌疾患の有病率の増加が、内分泌治療薬の需要を大きく牽引しています。

内分泌治療薬市場の主要企業は、投薬管理を強化するために、すぐに使えるバイアルなどの革新的な製品の開発を優先しています。これらのプレフィルド容器やプレドーズ容器は、使用前の再構成や調製を不要にします。例えば、2022年12月、英国の製薬会社であるHikma Pharmaceuticals plcは、濃度100mcg/mLのReady-to-useバイアル入りレボチロキシンナトリウム注射剤を発売しました。この製剤は即時投与用に設計されており、調製ミスのリスクを低減し、患者の安全性を高めます。甲状腺機能低下症や粘液水腫昏睡などの治療に不可欠な、正確で一貫した投与が保証されます。さらに、このバイアルは、時間を節約し、緊急医療の場面で正確な投与を保証することで、ヘルスケアプロバイダーの効率を向上させます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界内分泌治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の内分泌治療薬市場：成長率分析
• 世界の内分泌治療薬市場の実績：規模と成長, 2019-2024
• 世界の内分泌治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界内分泌治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の内分泌治療薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 甲状腺機能亢進症
• 甲状腺機能低下症
• 糖尿病
• 多嚢胞性卵巣症候群
• 成長ホルモン疾患
• 下垂体疾患
• その他の適応症
• 世界の内分泌治療薬市場治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 糖尿病薬
• 甲状腺ホルモン異常症の薬
• ヒト成長ホルモン
• テストステロン補充療法
• その他の治療分野
• 世界の内分泌治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の内分泌治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• その他のエンドユーザー
• 世界の内分泌治療薬市場甲状腺機能亢進症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗甲状腺薬
• 放射性ヨウ素療法
• ベータ遮断薬
• 世界の内分泌治療薬市場甲状腺機能低下症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レボチロキシン系薬剤
• リオチロニンベースの薬剤
• 併用ホルモン療法
• 世界の内分泌治療薬市場糖尿病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリン療法
• 経口糖尿病薬（OAD）
• GLP-1受容体作動薬
• SGLT-2阻害剤
• DPP-4阻害剤
• 世界の内分泌治療薬市場多嚢胞性卵巣症候群（PCOS）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口避妊薬
• メトホルミン
• クロミフェンクエン酸塩
• 抗アンドロゲン
• 世界の内分泌治療薬市場成長ホルモン疾患の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えヒト成長ホルモン（rhGH）
• 成長ホルモン分泌促進剤
• 成長ホルモン受容体拮抗薬
• 世界の内分泌治療薬市場下垂体疾患の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ソマトスタチン類似体
• ゴナドトロピン
• ドーパミン作動薬
• 世界の内分泌治療薬市場、その他の適応症のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 副腎疾患
• 骨粗鬆症
• 副甲状腺疾患
• 男性ホルモンの不均衡

第7章 地域別・国別分析

• 世界の内分泌治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の内分泌治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 内分泌治療薬市場：競合情勢
• 内分泌治療薬市場：企業プロファイル
  • Johnson & Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• Biocon Limited
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Sandoz International GmbH
• Ipsen Pharma
• Ferring Pharmaceuticals Inc.
• Endocrine Pharma Private Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 内分泌治療薬市場2029：新たな機会を提供する国
• 内分泌治療薬市場2029：新たな機会を提供するセグメント
• 内分泌治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Endocrinology drugs are pharmaceutical treatments designed to manage and regulate disorders associated with the endocrine system, which includes glands such as the thyroid, pancreas, and adrenal glands. These drugs are used to treat conditions such as diabetes, thyroid disorders, growth hormone deficiencies, and hormonal imbalances, aiming to restore normal hormonal levels and improve the overall function of the endocrine system.

The primary conditions treated with endocrinology drugs include hyperthyroidism, hypothyroidism, diabetes, polycystic ovarian syndrome, growth hormone disorders, and pituitary gland disorders, among others. Hyperthyroidism, for example, is marked by an overproduction of thyroid hormones, causing symptoms such as weight loss, rapid heartbeat, and anxiety. Key therapy areas include diabetes medications, thyroid hormone disorder treatments, human growth hormone, testosterone replacement therapy, and others. These drugs are distributed through various channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, and are used by a range of end users, including hospitals, ambulatory surgical centers, and more.

The endocrinology drugs market research report is one of a series of new reports from The Business Research Company that provides endocrinology drugs market statistics, including endocrinology drugs industry global market size, regional shares, competitors with an endocrinology drugs market share, detailed endocrinology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the endocrinology drugs industry. This endocrinology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endocrinology drugs market size has grown strongly in recent years. It will grow from $33.26 billion in 2024 to $36.21 billion in 2025 at a compound annual growth rate (CAGR) of 8.86%. The growth during the historic period can be attributed to factors such as the rising global prevalence of diabetes, increased government initiatives, higher healthcare spending, a growing incidence of adrenal gland disorders, increased demand for insulin analogs, and a higher number of endocrinologists.

The endocrinology drugs market size is expected to see strong growth in the next few years. It will grow to $50.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.60%. The expected growth during the forecast period can be attributed to factors such as a growing diabetic population, a higher prevalence of endocrine disorders, more adolescents facing hormonal imbalances, and increasing obesity rates. Key trends for the forecast period include advancements in technology, the adoption of advanced drug delivery systems, the integration of digital health solutions, precision medicine, and combination therapies.

The rising prevalence of endocrine diseases is driving the growth of the endocrinology drugs market. Endocrine diseases are disorders that affect the endocrine system, leading to imbalances in hormone production or regulation, which disrupt normal bodily functions. Factors contributing to the increasing prevalence of endocrine diseases include lifestyle changes, an aging population, and improvements in diagnostic methods, which have all led to greater recognition and incidence of these conditions. Endocrinology drugs are designed to manage these diseases by regulating hormone levels, addressing glandular dysfunction, and restoring hormonal balance, thus improving health outcomes. For example, in May 2023, the National Library of Medicine reported that approximately 13 million people in the U.S. (about 4.78% of the population) suffer from undiagnosed endocrine disorders, with thyroid disease being one of the most prevalent, affecting 30% to 40% of patients treated in endocrine practices. This growing prevalence of endocrine diseases is significantly driving the demand for endocrinology drugs.

Leading companies in the endocrinology drugs market are prioritizing the development of innovative products, such as ready-to-use vials, to enhance medication administration. These pre-filled and pre-dosed containers eliminate the need for reconstitution or preparation before use. For example, in December 2022, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced Levothyroxine sodium injection in ready-to-use vials with a concentration of 100 mcg/mL. This formulation is designed for immediate application, reducing the risk of preparation errors and enhancing patient safety. It ensures precise and consistent dosing, which is essential for treating conditions such as hypothyroidism and myxedema coma. Additionally, these vials improve efficiency for healthcare providers by saving time and ensuring accurate administration in urgent care scenarios.

In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma Inc., a France-based company specializing in therapies for rare endocrine diseases. This acquisition is aimed at strengthening AstraZeneca's portfolio in rare endocrine diseases by integrating Amolyt Pharma's innovative pipeline of late-stage therapies. This move highlights the ongoing efforts by major pharmaceutical companies to expand their capabilities and offerings in the growing market for endocrinology drugs.

Major players in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited.

North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in endocrinology drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the endocrinology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endocrinology drugs market consists of sales of insulin analogs, antithyroid drugs, and anti-diabetic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Endocrinology Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on endocrinology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for endocrinology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The endocrinology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Hyperthyroidism; Hypothyroidism; Diabetes; Polycystic Ovarian Syndrome; Growth Hormone Disorders; Pituitary Gland Disorders; Other Indications
• 2) By Therapy Area: Diabetes Drugs; Thyroid Hormone Disorder Drugs; Human Growth Hormone; Testosterone Replacement Therapy; Others Therapy Areas
• 3) By Distribution Channel: Hospital pharmacies; Online Pharmacies; Retail pharmacies
• 4) By End User: Hospitals; Ambulatory Surgical Centers; Others End Users
• Subsegments:
• 1) By Hyperthyroidism: Antithyroid Medications; Radioactive Iodine Therapy; Beta Blockers
• 2) By Hypothyroidism: Levothyroxine-based Medications; Liothyronine-based Medications; Combination Hormonal Therapies
• 3) By Diabetes: Insulin Therapies; Oral Antidiabetic Drugs (OADs); GLP-1 Receptor Agonists; SGLT-2 Inhibitors; DPP-4 Inhibitors
• 4) By Polycystic Ovarian Syndrome (PCOS): Oral Contraceptives; Metformin; Clomiphene Citrate; Anti-Androgens
• 5) By Growth Hormone Disorders: Recombinant Human Growth Hormone (rhGH); Growth Hormone Secretagogues; Growth Hormone Receptor Antagonists
• 6) By Pituitary Gland Disorders: Somatostatin Analogs; Gonadotropins; Dopamine Agonists
• 7) By Other Indications: Adrenal Gland Disorders; Osteoporosis; Parathyroid Disorders; Male Hormonal Imbalances
• Companies Mentioned: Johnson & Johnson Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer Aktiengesellschaft; Novartis International AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Endocrinology Drugs Market Characteristics

3. Endocrinology Drugs Market Trends And Strategies

4. Endocrinology Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Endocrinology Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Endocrinology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Endocrinology Drugs Market Growth Rate Analysis
• 5.4. Global Endocrinology Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Endocrinology Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Endocrinology Drugs Total Addressable Market (TAM)

6. Endocrinology Drugs Market Segmentation

• 6.1. Global Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hyperthyroidism
• Hypothyroidism
• Diabetes
• Polycystic Ovarian Syndrome
• Growth Hormone Disorders
• Pituitary Gland Disorders
• Other Indications
• 6.2. Global Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diabetes Drugs
• Thyroid Hormone Disorder Drugs
• Human Growth Hormone
• Testosterone Replacement Therapy
• Other Therapy Areas
• 6.3. Global Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital pharmacies
• Online Pharmacies
• Retail pharmacies
• 6.4. Global Endocrinology Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Other End Users
• 6.5. Global Endocrinology Drugs Market, Sub-Segmentation Of Hyperthyroidism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antithyroid Medications
• Radioactive Iodine Therapy
• Beta Blockers
• 6.6. Global Endocrinology Drugs Market, Sub-Segmentation Of Hypothyroidism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levothyroxine-based Medications
• Liothyronine-based Medications
• Combination Hormonal Therapies
• 6.7. Global Endocrinology Drugs Market, Sub-Segmentation Of Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Therapies
• Oral Antidiabetic Drugs (OADs)
• GLP-1 Receptor Agonists
• SGLT-2 Inhibitors
• DPP-4 Inhibitors
• 6.8. Global Endocrinology Drugs Market, Sub-Segmentation Of Polycystic Ovarian Syndrome (PCOS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Contraceptives
• Metformin
• Clomiphene Citrate
• Anti-Androgens
• 6.9. Global Endocrinology Drugs Market, Sub-Segmentation Of Growth Hormone Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Human Growth Hormone (rhGH)
• Growth Hormone Secretagogues
• Growth Hormone Receptor Antagonists
• 6.10. Global Endocrinology Drugs Market, Sub-Segmentation Of Pituitary Gland Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Somatostatin Analogs
• Gonadotropins
• Dopamine Agonists
• 6.11. Global Endocrinology Drugs Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adrenal Gland Disorders
• Osteoporosis
• Parathyroid Disorders
• Male Hormonal Imbalances

7. Endocrinology Drugs Market Regional And Country Analysis

• 7.1. Global Endocrinology Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Endocrinology Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Endocrinology Drugs Market

• 8.1. Asia-Pacific Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Endocrinology Drugs Market

• 9.1. China Endocrinology Drugs Market Overview
• 9.2. China Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Endocrinology Drugs Market

• 10.1. India Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Endocrinology Drugs Market

• 11.1. Japan Endocrinology Drugs Market Overview
• 11.2. Japan Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Endocrinology Drugs Market

• 12.1. Australia Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Endocrinology Drugs Market

• 13.1. Indonesia Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Endocrinology Drugs Market

• 14.1. South Korea Endocrinology Drugs Market Overview
• 14.2. South Korea Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Endocrinology Drugs Market

• 15.1. Western Europe Endocrinology Drugs Market Overview
• 15.2. Western Europe Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Endocrinology Drugs Market

• 16.1. UK Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Endocrinology Drugs Market

• 17.1. Germany Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Endocrinology Drugs Market

• 18.1. France Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Endocrinology Drugs Market

• 19.1. Italy Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Endocrinology Drugs Market

• 20.1. Spain Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Endocrinology Drugs Market

• 21.1. Eastern Europe Endocrinology Drugs Market Overview
• 21.2. Eastern Europe Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Endocrinology Drugs Market

• 22.1. Russia Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Endocrinology Drugs Market

• 23.1. North America Endocrinology Drugs Market Overview
• 23.2. North America Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Endocrinology Drugs Market

• 24.1. USA Endocrinology Drugs Market Overview
• 24.2. USA Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Endocrinology Drugs Market

• 25.1. Canada Endocrinology Drugs Market Overview
• 25.2. Canada Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Endocrinology Drugs Market

• 26.1. South America Endocrinology Drugs Market Overview
• 26.2. South America Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Endocrinology Drugs Market

• 27.1. Brazil Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Endocrinology Drugs Market

• 28.1. Middle East Endocrinology Drugs Market Overview
• 28.2. Middle East Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Endocrinology Drugs Market

• 29.1. Africa Endocrinology Drugs Market Overview
• 29.2. Africa Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Endocrinology Drugs Market Competitive Landscape And Company Profiles

• 30.1. Endocrinology Drugs Market Competitive Landscape
• 30.2. Endocrinology Drugs Market Company Profiles
  • 30.2.1. Johnson & Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. Endocrinology Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories
• 31.4. GlaxoSmithKline plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Novo Nordisk A/S
• 31.9. Biocon Limited
• 31.10. Boehringer Ingelheim International GmbH
• 31.11. Mylan N.V.
• 31.12. Sandoz International GmbH
• 31.13. Ipsen Pharma
• 31.14. Ferring Pharmaceuticals Inc.
• 31.15. Endocrine Pharma Private Limited

32. Global Endocrinology Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Endocrinology Drugs Market

34. Recent Developments In The Endocrinology Drugs Market

35. Endocrinology Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Endocrinology Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Endocrinology Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Endocrinology Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer